What is the treatment for Sphingomonas paucimobilis infection, especially in the context of bromhidrosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Sphingomonas paucimobilis Infection

Fluoroquinolones, particularly ciprofloxacin, are the first-line treatment for Sphingomonas paucimobilis infections, including those associated with bromhidrosis. 1, 2

Antimicrobial Therapy Options

First-line Treatment:

  • Ciprofloxacin 500mg twice daily for 7-14 days depending on infection severity 3, 1
  • This is particularly effective for:
    • Skin and soft tissue infections (including bromhidrosis)
    • Urinary tract infections
    • Respiratory infections

Alternative Options (based on susceptibility testing):

  • Levofloxacin 750mg daily 3, 4
  • Carbapenems (such as meropenem) for severe infections 4
  • Beta-lactam/beta-lactamase inhibitor combinations (e.g., piperacillin-tazobactam) 2

Treatment Algorithm Based on Infection Site

For Bromhidrosis Associated with S. paucimobilis:

  1. Oral ciprofloxacin 500mg twice daily for 7 days 1
  2. Concurrent use of antibacterial soap and topical antibacterial agents
  3. Follow-up after one week to confirm resolution

For Bloodstream Infections:

  1. Obtain blood cultures before initiating therapy
  2. Empiric therapy: Fluoroquinolone (ciprofloxacin or levofloxacin) 2
  3. Adjust therapy based on susceptibility results
  4. Treatment duration: 10-14 days 3
  5. Remove any infected catheters if catheter-related bloodstream infection is suspected 5

For Peritoneal Dialysis-Associated Peritonitis:

  1. Intraperitoneal plus intravenous antibiotics based on susceptibility 6
  2. Consider catheter removal if no improvement after 72 hours of appropriate therapy 5, 6

Special Considerations

Immunocompromised Patients:

  • Consider longer treatment duration (14+ days) 3
  • More aggressive monitoring for treatment response
  • Lower threshold for combination therapy in severe infections 3

Endocarditis:

  • Extended therapy (4-6 weeks)
  • Consider combination therapy with meropenem and levofloxacin for severe cases 4

Monitoring Response

  • Clinical improvement should be evident within 72 hours 3
  • If no improvement after 72 hours:
    • Repeat cultures
    • Consider alternative diagnoses
    • Evaluate for complications (abscess, endocarditis)
    • Consider changing antimicrobial therapy

Important Caveats

  • Despite being considered a low-virulence organism, S. paucimobilis can cause serious infections including septic shock 2
  • Resistance patterns vary, so antimicrobial susceptibility testing is crucial
  • For bromhidrosis specifically, addressing the underlying bacterial cause rather than just symptomatic treatment leads to better outcomes 1, 7
  • In cases of catheter-related infections, catheter removal may be necessary for complete resolution 5, 6

The case report of bromhidrosis caused by S. paucimobilis demonstrated complete resolution after one week of ciprofloxacin treatment 1, suggesting that targeted antimicrobial therapy addressing the specific pathogen is highly effective for this condition.

References

Research

Bromhidrosis induced by sphingomonas paucimobilis: a case report.

International journal of immunopathology and pharmacology, 2009

Research

Sphingomonas paucimobilis bacteremia in humans: 16 case reports and a literature review.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2010

Guideline

Treatment of Pseudomonas Aeruginosa Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Sphingomonas paucimobilis peritonitis: A case report and review of the literature.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.